Clinical Data, Inc. Plays Integral Role In MicroArray Quality Control (MAQC) Consortium Project; FDA-Led Initiative Assessing Reproducibility Of Microarray Data Featured In September 2006 Edition Of Nature Biotechnology

NEWTON, Mass.--(BUSINESS WIRE)--Sept. 8, 2006--Cogenics, a division of Clinical Data Inc. (NASDAQ: CLDA) and comprised of the combined companies of Genaissance Pharmaceuticals, Lark (US and UK), Icoria, and Genome Express of France, today joined with other participants of the MicroArray Quality Control (MAQC) Consortium in publishing the results of the FDA-led initiative to assess the precision, reproducibility and comparability of microarray gene expression data. Cogenics contribution was unique in the generation and analysis of multi-platform gene expression data and resulted in three publications in the September 2006 issue of Nature Biotechnology.

Back to news